Signant’s eCOA and oncology experts discuss the key takeaways from the FDA’s draft guidelines on patient-reported outcomes in oncology trials and its implications for trial design.
The discussion covers four key aspects of the FDA guidance and provides recommendations about:
- Current patient-reported outcome measures (PROMs) labelling & oncology challenges
- How to address PROM specificitiy: core measurement domains
- Ideal measurement timing & frequency
- Changes needed for eCOA design and implementation
Watch the webinar to ensure you’re properly prepared to meet FDA expectations in your cancer trials.
